Alvotech: European Commission Approves Mynzepli As Biosimilar To Eylea

(RTTNews) - Alvotech (ALVO) and Advanz Pharma Holdco announced that the European Commission has approved Mynzepli as a biosimilar to Eylea or aflibercept, in a pre-filled syringe and vial. The centralized marketing authorization is valid in all European Economic Area countries.

Mynzepli is approved for all adult indications approved for the reference biologic, neovascular or wet age-related macular degeneration, or visual impairment due to macular oedema secondary to retinal vein occlusion, diabetic macular oedema or myopic choroidal neovascularization.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.